全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Biological Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo

DOI: 10.4236/wja.2023.131001, PP. 1-10

Keywords: Biological Profile, PLHIV, Starting ART, Kinshasa

Full-Text   Cite this paper   Add to My Lib

Abstract:

Context: The biochemical assessment is a real-time indicator of the state and evolution of an infection. Among other things, it makes it possible to determine the right moment when it becomes necessary to start or change a treatment. Objective: The objective of this study is to present the Biological profile of People Living with HIV starting AntiRetroViral treatment in Kinshasa in the era of Dolutegravir. Methods: The present study is a descriptive cross-sectional to determine the biological profile of People Living with HIV (PLHIV) starting AntiRetroViral Treatment (ART). The patient inclusion period was from October 4, 2021 to February 15, 2022. Sixteen centers were included. A sample of 5 ml of blood was taken in a tube with EDTA. Patients were randomly included consecutively in the centers during consultations. The population was made up of adults aged over 18, infected with HIV and starting ART. The parameters of interest retained for the present study were: sex, age, hemoglobin level, blood sugar, urea, creatinine, transaminases, total cholesterol, triglycerides, proteins total, as well as amylase. Results: 119 patients were included in this study in accordance with the inclusion criteria; 67 (56.3%) are female, giving a sex ratio of 1.29 in favor of women. The average age of the patients is 39.87 ± 12.36 years. The most represented age group is that of 36 to 45 years with 37 patients (31.9%). The mean values of the biological parameters of the patients at the start of ART are as follows: 31.61 ± 20.71 IU/L for ALT/SGPT, 25.81 ± 19.96 IU/L for AST/SGOT, 79.35 ± 49.49 IU/L for Amylase, 108.13 ± 62.17 mg/dl for Total Cholesterol, 2.77 ± 1.27 mg/dl for Creatinine, 72.53 ±22.23 mg/dl for Glycaemia, 10.30 ± 2.33 g/dl for Hemoglobin, 7.91 ± 1.75 g/dl for Total Protein, 131.23 ± 68.80 mg/dl for Triglycerides, and 33.61 ± 26.27 mg/dl for Urea. Conclusion: Mean values of PLHIV are, for the most part, within the normal range. The average creatinine is higher than the normal average value while the average total cholesterol is below the limit values.

References

[1]  United Nations AIDS Program (UNAIDS) (2020) Country Factsheets: Democratic Republic of the Congo.
https://www.unaids.org/en/regionscountries/countries/democraticrepublicofthecongo
[2]  Organisation Mondiale de la Santé (OMS) (2016) Mettre fin au VIH/SIDA d’ici 2030; Cadre d’action dans la région Africaine de l’OMS 2016-2022.
https://apps.who.int/iris/bitstream/handle/10665/260473/EndAIDS-fre.pdf
[3]  World Health Organization (WHO) (2015) Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization, Geneva.
[4]  Girum, T., Yasin, F., Wasie, A., Shumbej, T., Bekele, F. and Zeleke, B. (2020) The Effect of “Universal Test and Treat” Program on HIV Treatment Outcomes and Patient Survival among a Cohort of Adults Taking Antiretroviral Treatment (ART) in Low Income Settings of Gurage Zone, South Ethiopia. AIDS Research and Therapy, 17, Article No. 19.
https://doi.org/10.1186/s12981-020-00274-3
[5]  Bongenia, I.B., Ilombo, L.L., Botomwito, T.H., Bulanda, I.B., Kamangu, N.E., Lusakibanza, L.M. and Mesia, K.G. (2014) Suivi des Paramètres Biologiques des patients sous antirétroviraux à l’Hôpital Provincial Général de Référence de Kinshasa de 2006 à 2012. Journal des Recherches BioMédicales, 1, 7-11.
[6]  Losenga, L.O., Dikati, N.M., Bongenya, B.I., Ntumba, T.K., Booto, G.I., Dembo, R.D., Selenge, S.M., Nonga, J.E., Kabamba, C.A., Sombo, M.-T.A.S., Bumoko, G.M.M. and Kamangu, E.N. (2022) Sociodemographic and Anthropometric Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo. Open Access Library Journal, 9, e9056.
https://doi.org/10.4236/oalib.1109056
[7]  Kamangu, N.E., Bulanda, I.B., Bongenia, I.B., Botomwito, T.H., Mvumbi, L.G., De Mol, P., Vaira, D., Hayette, M.-P. and Kalala, L.R. (2015) Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa. Open Access Library Journal, 2, e1564.
https://doi.org/10.4236/oalib.1101564
[8]  Bongenya, B.I., Bukongo, R.N., Bulanda, B.I., Chuga, D., Kabasele, J.Y.K., Okonda, M.O., Tshisumbu, C. and Kamangu, N.E. (2018) Gender Difference in Early Treatment Patients for Human Immunodeficiency Virus Type 1 Infection in Kinshasa, Democratic Republic of Congo. Mathews Journal of HIV/AIDS, 3, Article No. 18.
[9]  Mbula, M.M.K., Situakibanza, H.N.T., Mananga, L.G., Longokolo, M.M., Mandina, N.M., Mayasi, N.N., Mbula, M.M., Bepouka, B., Amaela, E.N., Tshilumba, D.N., Odio, O., Nkodila, A. and Longo Mbenza, B. (2020) Profil clinique et biologique des Personnes Vivant avec le VIH/SIDA suivies dans le Service des Maladies Infectieuses des Cliniques Universitaires de Kinshasa, République Démocratique du Congo. Revue Malienne d’Infectiologie et de Microbiologie, 15, 21-29.
https://doi.org/10.53597/remim.v15i2.1727
[10]  Durand, G. and Beaudeux, J.L. (2011) Biochimie médicale: Marqueurs actuels et perspectives. 2nd Edition, Médecines et Sciences Publications, Lavoisier.
[11]  Kamangu, N.E., Kalala, L.R., Mvumbi, L.G. and Mesia, K.G. (2012) Comparative Analysis of Serum Protein Electrophoresis’ Profiles of People Infected with HIV and Those Not Infected with HIV in Kinshasa. International Journal of Collaborative Research on Internal Medicine & Public Health, 4, 876-884.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133